plerixafor has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barwick, B; Boise, L; Chen, HR; Chen, J; Dong, JT; Fu, C; Kowalski, J; Kucuk, O; Li, M; Li, X; Li, Y; Osunkoya, AO; Qian, WP; Vertino, PM; Wu, D; Wu, Q; Xia, S; Xie, L; Yang, L; Zhang, B; Zhao, Y; Zhou, W | 1 |
1 other study(ies) available for plerixafor and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclams; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Interleukin-11; Kruppel-Like Transcription Factors; Male; Mice; Mutation; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Signal Transduction; Transforming Growth Factor beta | 2021 |